title: Cellular proliferative and telomerase activity in canine mammary gland tumors.
abstract: In canine mammary tumors, we examined the telomerase activity, proliferative activity by proliferative cell nuclear antigen (PCNA) immunohistochemistry, and percentage of apoptotic cells by the deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method. The relationship between these measures and histopathologic malignancy was also investigated. PCNA index was highest in malignant tumors (adenocarcinoma: 27.0%; malignant mixed tumor: 15.7%), followed by benign tumors (adenoma: 4.4%; benign mixed tumor: 5.3%), hyperplasia (2.1%), and normal mammary gland (0.9%). In adenoma and adenocarcinoma, papillary and solid types showing higher cellularity tended to have higher PCNA indices than did cystic and tubular types. Although the TUNEL index was <1% in all cases, the relationship between this measure and histopathologic diagnosis showed the same tendency as observed in PCNA immunostaining. Telomerase activity was detectable in all adenomas, benign mixed tumors, and adenocarcinomas examined. In contrast, all normal mammary glands, hyperplasias, and malignant mixed tumors were negative for telomerase. Relative telomerase activity (RTA) of adenocarcinoma (56.5) was significantly higher than that of adenoma (27.8) and benign mixed tumor (33.9), and a significant positive correlation (P < 0.001) was noted between RTA and PCNA index. No significant correlations were noted between either PCNA or TUNEL index and clinical features such as metastasis and tumor diameter. PCNA index and telomerase activity may be useful markers for judging malignancy of canine mammary tumors.
authors.affiliation: Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Funakoshi
authors.forename: H
authors.initials: H
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Uetsuka
authors.forename: R
authors.initials: R
authors.lastname: Nishimura
authors.forename: N
authors.initials: N
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Doi
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology / Q000662:veterinary*; D000236:Adenoma / Q000201:enzymology / Q000473:pathology / Q000662:veterinary*; D000818:Animals; D002455:Cell Division; D053938:DNA Fragmentation; D017931:DNA Primers / Q000737:chemistry; D004273:DNA, Neoplasm / Q000737:chemistry; D004283:Dog Diseases / Q000201:enzymology / Q000473:pathology*; D004285:Dogs; D005260:Female; D006965:Hyperplasia / Q000201:enzymology / Q000473:pathology / Q000662:veterinary; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling / Q000662:veterinary; D008321:Mammary Glands, Animal / Q000201:enzymology / Q000473:pathology*; D015674:Mammary Neoplasms, Animal / Q000737:chemistry / Q000201:enzymology / Q000473:pathology*; D016133:Polymerase Chain Reaction / Q000662:veterinary; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D019098:Telomerase / Q000032:analysis*
chemical_list: D017931:DNA Primers; D004273:DNA, Neoplasm; D018809:Proliferating Cell Nuclear Antigen; D019098:Telomerase